Plasma Protease C1-inhibitor Treatment Market

Plasma Protease C1-inhibitor Treatment Market (Drug Class- C1-inhibitors (C1-esterase Inhibitor and Recombinant Inhibitor), Kallikrein Inhibitor (Kalbitor), and Selective Bradykinin B2 Receptor Antagonist (Firazyr); Distribution Channel - Hospital Pharmacies and Independent Pharmacies and Outlets; Dosage Type - Lyophilized and Liquid/Injectable) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2025

Global Plasma Protease C1-inhibitor Treatment Market: Snapshot

The global plasma protease C1-inhibitor treatment market is foreseen to display robust growth in the future due to the increasing cases of acute hereditary angioedema (HAE) and prophylaxis. The emergence of a few drug variants of C1-inhibitor is considered to be a major breakthrough for patients suffering from HAE that are administered either intravenously or subcutaneously.

According to a report by Transparency Market Research (TMR), the global plasma protease C1-inhibitor treatment market was evaluated at US$1.5 bn in 2016. The report forecasts the demand in the global plasma protease C1-inhibitor market will rise at a robust 20.0% CAGR for the forecast period of 2017 to 2025, for the market to be valued at US$7.9 bn by the end of 2025.

plasma protease c1 inhibitor treatment market

 

Extensive Use for HAE Makes C1-inhibitor Drug Class Dominant

Based on drug class, the global plasma protease C1-inhibitor market is classified into C1-inhibitor, Kallikrein inhibitor, and selective Bradykinin B2 receptor antagonist (Firazyr). The C1-inhibitor segment held the leading market share in 2016 as these drugs are widely used for the treatment of acute HAE and prophylaxis. The segment of Selective Bradykining B2 Receptor is anticipated to display the leading growth rate over the forecast period. This is mainly because of expanding R&D activities that key players are engaged in for the development of new C1-inhibitor deficiency drugs that can be administered subcutaneously. On the other hand, the segment of Kallikrein inhibitor (Kalbitor) is predicted to register a moderate CAGR between 2017 and 2025. The growth of Kallikrein inhibitor segment is attributable to the rising preference for self-administrable drugs. Moreover, the rising preference for Firazyr is anticipated to hamper the growth of Kalbitor segment. However, increasing approval of Kallikrein drugs and positive results obtained for pre-clinical treatment of HAE cases are likely to augment the growth rate of this segment moderately over the forecast period.

On the basis of dosage type, the market is segregated into lyophilized and liquid/injectable. Of the two, lyophilized segment held the leading market share in 2016 on the back of increasing practice of intravenous administration of drugs for the treatment of HAE. Further, rising demand for intravenous C1 esterase inhibitor drugs in emerging markets of Asia Pacific and Latin America is anticipated to positively influence the lyophilized segment.

However, the liquid/injectable segment is likely to hold significant market share by 2025 due to several factors. This includes rising demand for subcutaneous administration of drugs, less adverse effects, cost effectiveness, and increased preference for Firazyr over Kalbitor by physicians. The expected launch of subcutaneous Cinryze, Berinert, and DX-2930 will further hamper the growth of lyophilized segment. To stay competitive, companies are vying to introduce the subcutaneous variants of Cinryze and Berinet for prophylactic treatment and are expected to be commercially available by 2019 and 2018 respectively. Despite the liquid/injectable nature of Firazyr and Kalbitor the side-effects associated with them can hamper the liquid/injectable segment over the forecast period.

In terms of distribution channel, the market has been bifurcated into hospital pharmacies and independent pharmacies & outlets in this report. Of the two, independent pharmacies & outlets dominated the market in 2016; the segment is anticipated to hold dominance through 2025.

North America to Lead Plasma Protease C1-inhibitor Treatment Market through 2025

Geographically, the plasma protease C1-inhibitor treatment market is divided into four key regions, namely North America, Europe, Latin America, and Rest of the World. Among these, North America stood as the leading contributor to the worldwide market for plasma protease C1-inhibitor treatment market in 2016. High prevalence of HAE in the U.S. that are actually diagnosed and treated using C1-inhibitor drugs account for the leading growth of this regional market.

The global plasma protease C1-inhibitor treatment market features a highly consolidated vendor landscape. Shire plc, Pharming Group N.V., CSL Limited, and Sanquin are the key companies operating in this market.

Researchers Conscious about Risks of Angioedema to Boost Efficacy of Products in Plasma Protease C1-inhibitor Treatment Market

Human plasma-derived C1-esterase inhibitor has emerged as an effective and safe treatment for hereditary angioedema. The growing incidence of acute hereditary angioedema (HAE) and prophylaxis has propelled research on finding ways to administer and regulate C1-esterase inhibitor (C1-INH), thereby propelling the evolution of the plasma protease C1-inhibitor treatment market. The role of this is crucial in understanding the pathophysiology of HAE and the concentration of complexes C1-esterase inhibitor forms with proteases. Various tests and biomarkers have been developed to ascertain C1-INH deficiency, the reason having to do with the high morbidity and mortality of HAE in patient populations all over the world. Research on finding all possible ways of activating all C1-INH-regulated pathways are stridently expanding the possibilities in the plasma protease C1-inhibitor treatment market. In this regard, advances made in purified proteins and antibodies have expanded the prospects in the market. However, a common side effect in all treatment can be prothrombotic effects. To overcome the constraints, researchers have embarked on evaluating results from a number of vitro assays of coagulation markers and in vivo studies. Various animal models have helped them in their endeavors.

The COVID-19 pandemic and the various waves have played havoc with the healthcare systems of countries across the world. Developed and emerging nations have also been finding it hard to mitigate the morbidity of the disease. The death rates have also reached alarming levels in 2020 in numerous regions across the globe. The ugly aftermath of the pandemic on the economic systems continue to alarm governments and businesses across all industries. Thus, industry players have joined hands to concertedly combat the humanitarian crisis. They are also coming out with new models to connect with prospective customers and adopting strategies to emerge as responsibly organization amid the pandemic. The full impact of plasma protease C1-inhibitor treatment market is still to be ascertained. Unarguably, the pandemic has impeded research and clinical trials, raising the ante for businesses to gain competitiveness in the market.

The Global Plasma Protease C1-inhibitor Treatment Market is segmented as given below:

by Drug Class 

  • C1-inhibitors
    • C1-esterase Inhibitor
    • Recombinant Inhibitor
  • Kallikrein Inhibitor (Kalbitor)
  • Selective Bradykinin B2 Receptor Antagonist (Firazyr)
  •  

by Dosage Type

  • Liquid/Injectable
  • Lyophilized

by Distribution Channel

  • Hospital Pharmacies
  • Independent Pharmacies and Outlets

By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • EU-5 Countries
    • BENELUX Countries
    • Rest of Europe
  • Latin America
    • Argentina
    • Brazil
    • Rest of Latin America
  • Rest of World
    • Australia
    • Israel
  • Rest of World Countries

    1. Preface
          1.1. Market Definition and Scope
          1.2. Market Segmentation
          1.3. Key Research Objectives
          1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary : Global Plasma Protease C1-Inhibitor Treatment Market 

    4. Market Overview
          4.1. Introduction
          4.2.  Overview
          4.3. Key Market Indicators
          4.4. Market Dynamics
                  4.4.1. Drivers
                  4.4.2. Restraints
                  4.4.3. Opportunity
          4.5. Global Plasma Protease C1-Inhibitor Treatment Market  Analysis and Forecasts, 2015–2025
                  4.5.1. Market Revenue Projections (US$ Mn)
          4.7. Porter’s Five Force Analysis
          4.8. Market Outlook
          4.9. Regulatory Scenario
          4.10. Pipeline Analysis and  Patent Launch/Expiry
          4.11. Therapeutic Application & Biological Activities: C1-Esterase Inhibitor
          4.12. Global Number of Procedures of Hereditary Angioedema Disease
          4.13. Brand Analysis Plasma Protease C1-Inhibitor Drugs
          4.14. Product Portfolio of Human C1-INH Plasma Protein
          4.15. Research Institutes Involved In Hereditary Angioedema/Others Disease

    5. Global Plasma Protease C1-Inhibitor Treatment Market  Analysis and Forecasts, By Drug Class 
          5.1. Introduction & Definition
          5.2. Key Trends
          5.3. Market  Forecast By Drug Class, 2015–2025
                  5.3.1. C1-Inhibitor
                            5.3.1.1. C1-Esterase Inhibitor
                            5.3.1.2. Recombinant Inhibitor
                  5.3.2. Kallikrein Inhibitor (Kalbitor)
                  5.3.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr)
          5.4. Market Attractiveness By Drug Class 

    6. Global Plasma Protease C1-Inhibitor Treatment Market  Analysis and Forecasts, By Dosage Type 
          6.1. Introduction & Definition
          6.2. Market  Forecast By Dosage Type, 2015–2025
                  6.2.1. Lyophilized
                  6.2.2. Liquid/Injectable
          6.3. Market Attractiveness By Dosage Type 

    7. Global Plasma Protease C1-Inhibitor Treatment Market  Analysis and Forecasts, By Distribution Channel  
          7.1. Introduction & Definition
          7.2. Key Trends
          7.3. Market  Forecast By Distribution Channel , 2015–2025
                  7.3.1. Hospital Pharmacies
                  7.3.2. Independent Pharmacies and Outlets
          7.4. Market Attractiveness By Distribution Channel  

    8. Global Plasma Protease C1-Inhibitor Treatment Market  Analysis and Forecasts, By Region
          8.1. Key Findings
          8.2. Market  Forecast By Region
                  8.2.1. North America 
                  8.2.2. Europe 
                  8.2.3. Latin America 
                  8.2.4. Rest of World 
          8.4. Market Attractiveness By Country/Region

    9. North America Plasma Protease C1-Inhibitor Treatment Market  Analysis and Forecast
          9.1. Introduction
                  9.1.1. Key Trends
          9.2. Market  Forecast By Drug Class, 2015–2025
                  9.2.1. C1-Inhibitor
                            9.2.1.1. C1-Esterase Inhibitor
                            9.2.1.2. Recombinant Inhibitor
                  9.2.2. Kallikrein Inhibitor (Kalbitor)
                  9.2.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr)
          9.3. Market  Forecast By Dosage Type, 2015–2025
                  9.3.1. Lyophilized
                  9.3.2. Liquid/Injectable      
          9.4. Market  Forecast By Distribution Channel , 2015–2025
                  9.4.1. Hospital Pharmacies
                  9.4.2. Independent Pharmacies and Outlets
          9.5. Market  Forecast By Country, 2015–2025
                  9.5.1. U.S.
                  9.5.2. Canada
          9.6. Market Attractiveness Analysis 
                  9.6.1. By Drug Class 
                  9.6.2. By Dosage Type 
                  9.6.3. By Distribution Channel  
                  9.6.4. By Country

    10. Europe Plasma Protease C1-Inhibitor Treatment Market  Analysis and Forecast
          10.1. Introduction
                  10.1.1. Key Trends
          10.2. Market Forecast By Drug Class, 2015–2025
                  10.2.1. C1-Inhibitor
                            10.2.1.1. C1-Esterase Inhibitor
                            10.2.1.2. Recombinant Inhibitor
                  10.2.2. Kallikrein Inhibitor (Kalbitor)
                  10.2.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr)
          10.3. Market  Forecast By Dosage Type, 2015–2025
                  10.3.1. Lyophilized
                  10.3.2. Liquid/Injectable
          10.4. Market  Forecast By Distribution Channel, 2015–2025
                  10.4.1. Hospital Pharmacies
                  10.4.2. Independent Pharmacies and Outlets
          10.5. Market  Forecast By Country, 2015–2025
                  10.5.1. EU-5 Countries
                  10.5.2. BENELUX Countries
                  10.5.3. Rest of Europe
          10.6. Market Attractiveness Analysis 
                  10.6.1. By Drug Class 
                  10.6.2. By Dosage Type 
                  10.6.3. By Distribution Channel  
                  10.6.4. By Country

    11. Latin America Plasma Protease C1-Inhibitor Treatment Market  Analysis and Forecast      
          11.1. Introduction
                  11.1.1. Key Trends
          11.2. Market  Forecast By Drug Class, 2015–2025
                  11.2.1. C1-Inhibitor
                            11.2.1.1. C1-Esterase Inhibitor
                            11.2.1.2. Recombinant Inhibitor
                  11.2.2. Kallikrein Inhibitor (Kalbitor)
                  11.2.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr)
          11.3. Market  Forecast By Dosage Type, 2015–2025
                  11.3.1. Lyophilized
                  11.3.2. Liquid/Injectable
          11.4. Market  Forecast By Distribution Channel, 2015–2025
                  11.4.1. Hospital Pharmacies
                  11.4.2. Independent Pharmacies and Outlets
          11.5. Market  Forecast By Country, 2015–2025
                  11.5.1. Argentina
                  11.5.2. Brazil
                  11.5.3. Rest of Latin America
          11.6. Market Attractiveness Analysis 
                  11.6.1. By Drug Class 
                  11.6.2. By Dosage Type 
                  11.6.3. By Distribution Channel  
                  11.6.4. By Country

    12. Rest of World Plasma Protease C1-Inhibitor Treatment Market  Analysis and Forecast
          12.1. Introduction
                  12.1.1. Key Trends
          12.2. Market  Forecast By Drug Class, 2015–2025
                  12.2.1. C1-Inhibitor
                            12.2.1.1. C1-Esterase Inhibitor
                            12.2.1.2. Recombinant Inhibitor
                  12.2.2. Kallikrein Inhibitor (Kalbitor)
                  12.2.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr)
          12.3. Market  Forecast By Dosage Type, 2015–2025
                  12.3.1. Lyophilized
                  12.3.2. Liquid/Injectable
          12.4. Market  Forecast By Distribution Channel, 2015–2025
                  12.4.1. Hospital Pharmacies
                  12.4.2. Independent Pharmacies and Outlets
          12.5. Market  Forecast By Country, 2015–2025
                  12.5.1. Australia
                  12.5.2. Israel
                  12.5.3. Rest of World Countries
          12.6. Market Attractiveness Analysis 
                  12.6.1. By Drug Class 
                  12.6.2. By Dosage Type 
                  12.6.3. By Distribution Channel  
                  12.6.4. By Country

    13. Competition Landscape
          13.1. Market Player – Competition Matrix (By Tier and Size of companies)
          13.2. Market Share Analysis By Company (2016)
          13.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
                  13.3.1. Shire plc
                            13.3.1.1. Overview (HQ, Employee Strength, Business Segments)
                            13.3.1.2. Financials
                            13.3.1.3. Recent Developments
                            13.3.1.4. Strategy
                  13.3.2. Pharming Group N.V.
                            13.3.2.1. Overview (HQ, Employee Strength, Business Segments)
                            13.3.2.2. Financials
                            13.3.2.3. Recent Developments
                            13.3.2.4. Strategy
                  13.3.3. Sanquin
                            13.3.3.1. Overview (HQ, Employee Strength, Business Segments)
                            13.3.3.2. Financials
                            13.3.3.3. Recent Developments
                            13.3.3.4. Strategy
                  13.3.4. CSL Limited
                            13.3.4.1. Overview (HQ, Employee Strength, Business Segments)
                            13.3.4.2. Financials
                            13.3.4.3. Recent Developments
                            13.3.4.4. Strategy

    14. Key Take Aways

    List of Tables

    Table 01: Pipeline Analysis-Phase 3-by Product/Drug Candidate, 2015-2017
    Table 02: Pipeline Analysis-Phase 1 & 2 – Preclinical-by Product/Drug Candidate, 2014-2016
    Table 03: Pipeline Analysis-Recombinant Hormone/Drugs-by Product/Drug Candidate 
    Table 04: Pipeline Analysis-Recombinant Hormone/Drugs-by Product/Drug Candidate  
    Table 05: Pipeline Analysis-Recombinant Hormone/Drugs-by Product/Drug Candidate 
    Table 06: Pipeline Analysis-Recombinant Hormone/Drugs-by Product/Drug Candidate 
    Table 07: Pipeline Analysis-Recombinant Hormone/Drugs-by Product/Drug Candidate 
    Table 08: Pipeline Analysis-Recombinant Hormone/Drugs-by Product/Drug Candidate 
    Table 09: Pipeline Analysis-Recombinant Hormone/Drugs-by Product/Drug Candidate 
    Table 10: Pipeline Analysis-Recombinant Hormone/Drugs-by Product/Drug Candidate 
    Table 11: Orphan Drug Exclusivity-by Approval & Expiry
    Table 12: Orphan Drug Exclusivity-by Approval & Expiry
    Table 13: Orphan Drug Exclusivity-by Approval & Expiry
    Table 14: Product Portfolio of Human C1-INH Plasma Protein-by Sponsor/Company
    Table 15: Global Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2015–2025
    Table 16: Global Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Drug Class – C1-Inhibitor, 2015-2025
    Table 17: Global Plasma Protease C1-inhibitor Treatment Market Value (US$ Mn) Forecast, by Dosage Type, 2015–2025
    Table 18: Global Plasma Protease C1-inhibitor Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 19: Global Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Region, 2015–2025
    Table 20: North America Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Country, 2015-2025
    Table 21: North America Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2015–2025
    Table 22: North America Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Drug Class – C1-Inhibitor, 2015–2025
    Table 23: North America Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Dosage Type, 2015–2025
    Table 24: North America Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 25: Europe Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Country, 2015–2025
    Table 26: Europe Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2015–2025
    Table 27: Europe Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Drug Class – C1-Inhibitor, 2015–2025
    Table 28: Europe Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Dosage Type, 2015–2025
    Table 29: Europe Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 30: Latin America Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Country,
    Table 31: Latin America Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2015–2025
    Table 32: Latin America Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Drug Class – C1-Inhibitor, 2015–2025
    Table 33: Latin America Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Dosage Type, 2015–2025
    Table 34: Latin America Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 35: Rest of the World Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Country, 2015–2025
    Table 36: Rest of the World Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2015–2025
    Table 37: Rest of the World Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Drug Class – C1-Inhibitor, 2015–2025
    Table 38: Rest of the World Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Dosage Type, 2015–2025
    Table 39: Rest of the World Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025

    List of Figures

    FIG 01: Global Plasma Protease C1-Inhibitor Treatment Market Size (US$ Mn) Forecast, 2015–2025
    FIG 02: Global Plasma Protease C1-Inhibitor Treatment Market Value Share, by Drug Class (2016)
    FIG 03: Global Plasma Protease C1-Inhibitor Treatment Market Value Share, by Region (2016)
    FIG 04: Global Plasma Protease C1-Inhibitor Treatment Market Value Share, by Distribution Channel (2016)
    FIG 05: Global Plasma Protease C1-Inhibitor Treatment Market Value Share, by Dosage Type (2016)
    FIG 06: Global Plasma Protease C1-Inhibitor Treatment Market Value Share, by Drug Class, 2017 and 2025
    FIG 07: Global Plasma Protease C1-Inhibitor Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by C1-Inhibitor, 2015–2025
    FIG 08: Global Plasma Protease C1-Inhibitor Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Kallikrein Inhibitor, 2015-2017
    FIG 09: Global Plasma Protease C1-Inhibitor Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Selective Bradykinin B2 Receptor Antagonist, 2015–2025
    FIG 10: Global Plasma Protease C1-Inhibitor Treatment Market Attractiveness, by Drug Class, 2017–2025
    FIG 11: Global Plasma Protease C1-inhibitor Treatment Market Value Share, by Dosage Type, 2017 and 2025
    FIG 12: Global Plasma Protease C1-inhibitor Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Lyophilized, 2015–2025
    FIG 13: Global Plasma Protease C1-inhibitor Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Liquid/Injectable, 2015–2025
    FIG 14: Global Plasma Protease C1-inhibitor Treatment Market Attractiveness, by Dosage Type, 2017–2025
    FIG 15: Global Plasma Protease C1-inhibitor Treatment Market Value Share, by Distribution Channel, 2017 and 2025
    FIG 16: Global Plasma Protease C1-inhibitor Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2015–2025
    FIG 17: Global Plasma Protease C1-inhibitor Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Independent Pharmacies & Outlets, 2015–2025
    FIG 18: Global Plasma Protease C1-inhibitor Treatment Market Attractiveness, by Distribution Channel, 2017–2025
    FIG 19: Global Plasma Protease C1-Inhibitor Treatment Market Value Share, by Region, 2017 and 2025
    FIG 20: Global Plasma Protease C1-Inhibitor Treatment Market Attractiveness, by Region, 2017–2025
    FIG 21: North America Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015–2025
    FIG 22: North America Plasma Protease C1-Inhibitor Treatment Market Value Share, by Country, 2017–2025
    FIG 23: North America Plasma Protease C1-Inhibitor Treatment Market Attractiveness, by Country, 2017–2025
    FIG 24: North America Plasma Protease C1-Inhibitor Treatment Market Value Share, by Drug Class, 2017 and 2025
    FIG 25: North America Plasma Protease C1-Inhibitor Treatment Market Attractiveness, by Drug Class, 2017–2025
    FIG 26: North America Plasma Protease C1-Inhibitor Treatment Market Value Share, by Dosage Type, 2017 and 2025
    FIG 27: North America Plasma Protease C1-Inhibitor Treatment Market Attractiveness, by Dosage Type, 2017–2025
    FIG 28: North America Plasma Protease C1-Inhibitor Treatment Market Value Share, by Distribution Channel, 2017 and 2025
    FIG 29: North America Plasma Protease C1-Inhibitor Treatment Market Attractiveness, by Distribution Channel, 2017–2025
    FIG 30: Europe Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015–2025
    FIG 31: Europe Plasma Protease C1-Inhibitor Treatment Market Value Share, by Country, 2017–2025
    FIG 32: Europe Plasma Protease C1-Inhibitor Treatment Market Attractiveness, by Country, 2017–2025
    FIG 33: Europe Plasma Protease C1-Inhibitor Treatment Market Value Share, by Drug Class, 2017 and 2025
    FIG 34: Europe Plasma Protease C1-Inhibitor Treatment Market Attractiveness, by Drug Class, 2017–2025
    FIG 35: Europe Plasma Protease C1-Inhibitor Treatment Market Value Share, by Dosage Type, 2017 and 2025
    FIG 36: Europe Plasma Protease C1-Inhibitor Treatment Market Attractiveness, by Dosage Type, 2017–2025
    FIG 37: Europe Plasma Protease C1-Inhibitor Treatment Market Value Share, by Distribution Channel, 2017 and 2025
    FIG 38: Europe Plasma Protease C1-Inhibitor Treatment Market Attractiveness, by Distribution Channel, 2017–2025
    FIG 39: Latin America Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015–2025
    FIG 40: Latin America Plasma Protease C1-Inhibitor Treatment Market Value Share, by Country, 2017–2025
    FIG 41: Latin America Plasma Protease C1-Inhibitor Treatment Market Attractiveness, by Country, 2017–2025
    FIG 42: Latin America Plasma Protease C1-Inhibitor Treatment Market Value Share, by Drug Class, 2017 and 2025
    FIG 43: Latin America Plasma Protease C1-Inhibitor Treatment Market Attractiveness, by Drug Class, 2017–2025
    FIG 44: Latin America Plasma Protease C1-Inhibitor Treatment Market Value Share, by Dosage Type, 2017 and 2025
    FIG 45: Latin America Plasma Protease C1-Inhibitor Treatment Market Attractiveness, by Dosage Type, 2017–2025
    FIG 46: Latin America Plasma Protease C1-Inhibitor Treatment Market Value Share, by Distribution Channel, 2017 and 2025
    FIG 47: Latin America Plasma Protease C1-Inhibitor Treatment Market Attractiveness, by Distribution Channel, 2017–2025
    FIG 48: Rest of the World Plasma Protease C1-Inhibitor Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015–2025
    FIG 49: Rest of the World Plasma Protease C1-Inhibitor Treatment Market Value Share, by Country, 2017–2025
    FIG 50: Rest of the World Plasma Protease C1-Inhibitor Treatment Market Attractiveness, by Country, 2017–2025
    FIG 51: Rest of the World Plasma Protease C1-Inhibitor Treatment Market Value Share, by Drug Class, 2017 and 2025
    FIG 52: Rest of the World Plasma Protease C1-Inhibitor Treatment Market Attractiveness, by Drug Class, 2017–2025
    FIG 53: Rest of the World Plasma Protease C1-Inhibitor Treatment Market Value Share, by Dosage Type, 2017 and 2025
    FIG 54: Rest of the World Plasma Protease C1-Inhibitor Treatment Market Attractiveness, by Dosage Type, 2017–2025
    FIG 55: Rest of the World Plasma Protease C1-Inhibitor Treatment Market Value Share, by Distribution Channel, 2017 and 2025
    FIG 56: Rest of the World Plasma Protease C1-Inhibitor Treatment Market Attractiveness, by Distribution Channel, 2017–2025
    FIG 57: Global Plasma Protease C1-Inhibitor Treatment Market Share, by Company, 2016 
    FIG 58: Breakdown of Net Sales (%), by Therapeutic Area, 2016
    FIG 59: Product Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
    FIG 60: Breakdown of Net Sales (%), by Major Products, 2016
    FIG 61: Sales Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
    FIG 62: Breakdown of Net Sales (%), by Therapeutic Area, 2016
    FIG 63: Product Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
    FIG 64: Breakdown of Net Sales (%), by Europe Region, 2016
    FIG 65: Plasma Product Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
    FIG 66: Product Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016

Copyright © Transparency Market Research, Inc. All Rights reserved